Weight loss market: Eli Lilly and Novo Nordisk's rivals muscle in
Briefly

from euronews4 months ago
Eli Lilly and Novo Nordisk dominate the weight-loss drug market, but smaller firms like Roche and Pfizer are developing treatments to compete for market share.
euronewshttps://www.euronews.com/business/2024/09/17/weight-loss-market-smaller-rivals-muscle-in-on-eli-lilly-and-novo-nordisk
Analysts predict the GLP-1 drug market could soar to $200bn by the 2030s, with Eli Lilly and Novo Nordisk commanding 44% and 36% market shares, respectively.
euronewshttps://www.euronews.com/business/2024/09/17/weight-loss-market-smaller-rivals-muscle-in-on-eli-lilly-and-novo-nordisk
Supply issues are troubling the weight-loss drug market, with Novo Nordisk confirming that these shortages are expected to continue through 2024.
euronewshttps://www.euronews.com/business/2024/09/17/weight-loss-market-smaller-rivals-muscle-in-on-eli-lilly-and-novo-nordisk
Novo Nordisk is expanding its manufacturing capabilities with a $4.1bn investment in a new plant in North Carolina to tackle supply constraints.
euronewshttps://www.euronews.com/business/2024/09/17/weight-loss-market-smaller-rivals-muscle-in-on-eli-lilly-and-novo-nordisk
Read at euronews
#weight-loss-drugs #pharmaceutical-industry #market-competition #glp-1-drugs #supply-constraints
[
|
]